Inhibition of human factor 9a using CH3SO2-DCHG-Gly-Arg-AFC.AcOH as substrate preinubated for 30 mins followed by substrate addition measured after 1 hr by fluorescence assay
Competitive binding affinity to human factor 9a expressed in Escherichia coli after 30 mins by ALIS-AS analysis in presence of (S)-2,6-Dichloro-N-(2-(7-fluoro-2-methyl-1H-benzo[d]-imidazol-5-yl)2-(3-fluorophenyl)ethyl)-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide
Drug level in human liver microsomes treated with (R)-2,6-Dichloro-N-(2-(3-fluorophenyl)-2-(2-methyl-1Hbenzo[d]imidazol-5-yl)ethyl)-4-(3-methyl-1H-1,2,4-triazol-1-yl)-benzamide after 4 hrs by LC-MS/MS analysis
Drug level in Sprague-Dawley rat liver microsomes treated with (R)-2,6-Dichloro-N-(2-(3-fluorophenyl)-2-(2-methyl-1Hbenzo[d]imidazol-5-yl)ethyl)-4-(3-methyl-1H-1,2,4-triazol-1-yl)-benzamide after 4 hrs by LC-MS/MS analysis
Drug level in beagle dog liver microsomes treated with (R)-2,6-Dichloro-N-(2-(3-fluorophenyl)-2-(2-methyl-1Hbenzo[d]imidazol-5-yl)ethyl)-4-(3-methyl-1H-1,2,4-triazol-1-yl)-benzamide at 100 uM after 4 hrs by LC-MS/MS analysis